Cargando…
FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310094/ https://www.ncbi.nlm.nih.gov/pubmed/25631039 http://dx.doi.org/10.1038/srep08114 |
_version_ | 1782354804175011840 |
---|---|
author | Lu, Weiqiang Cheng, Feixiong Jiang, Jing Zhang, Chen Deng, Xiaokang Xu, Zhongyu Zou, Shien Shen, Xu Tang, Yun Huang, Jin |
author_facet | Lu, Weiqiang Cheng, Feixiong Jiang, Jing Zhang, Chen Deng, Xiaokang Xu, Zhongyu Zou, Shien Shen, Xu Tang, Yun Huang, Jin |
author_sort | Lu, Weiqiang |
collection | PubMed |
description | Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elucidated. In this study, we developed a systems pharmacology approach to explore the mechanism-of-action of NSAIDs. We found that the Farnesoid X Receptor (FXR) antagonism of NSAIDs is a potential molecular mechanism of DILI through systematic network analysis and in vitro assays. Specially, the quantitative real-time PCR assay reveals that indomethacin and ibuprofen regulate FXR downstream target gene expression in HepG2 cells. Furthermore, the western blot shows that FXR antagonism by indomethacin induces the phosphorylation of STAT3 (signal transducer and activator of transcription 3), promotes the activation of caspase9, and finally causes DILI. In summary, our systems pharmacology approach provided novel insights into molecular mechanisms of DILI for NSAIDs, which may propel the ways toward the design of novel anti-inflammatory pharmacotherapeutics. |
format | Online Article Text |
id | pubmed-4310094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43100942015-02-09 FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach Lu, Weiqiang Cheng, Feixiong Jiang, Jing Zhang, Chen Deng, Xiaokang Xu, Zhongyu Zou, Shien Shen, Xu Tang, Yun Huang, Jin Sci Rep Article Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elucidated. In this study, we developed a systems pharmacology approach to explore the mechanism-of-action of NSAIDs. We found that the Farnesoid X Receptor (FXR) antagonism of NSAIDs is a potential molecular mechanism of DILI through systematic network analysis and in vitro assays. Specially, the quantitative real-time PCR assay reveals that indomethacin and ibuprofen regulate FXR downstream target gene expression in HepG2 cells. Furthermore, the western blot shows that FXR antagonism by indomethacin induces the phosphorylation of STAT3 (signal transducer and activator of transcription 3), promotes the activation of caspase9, and finally causes DILI. In summary, our systems pharmacology approach provided novel insights into molecular mechanisms of DILI for NSAIDs, which may propel the ways toward the design of novel anti-inflammatory pharmacotherapeutics. Nature Publishing Group 2015-01-29 /pmc/articles/PMC4310094/ /pubmed/25631039 http://dx.doi.org/10.1038/srep08114 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Lu, Weiqiang Cheng, Feixiong Jiang, Jing Zhang, Chen Deng, Xiaokang Xu, Zhongyu Zou, Shien Shen, Xu Tang, Yun Huang, Jin FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach |
title | FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach |
title_full | FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach |
title_fullStr | FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach |
title_full_unstemmed | FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach |
title_short | FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach |
title_sort | fxr antagonism of nsaids contributes to drug-induced liver injury identified by systems pharmacology approach |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310094/ https://www.ncbi.nlm.nih.gov/pubmed/25631039 http://dx.doi.org/10.1038/srep08114 |
work_keys_str_mv | AT luweiqiang fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT chengfeixiong fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT jiangjing fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT zhangchen fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT dengxiaokang fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT xuzhongyu fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT zoushien fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT shenxu fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT tangyun fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach AT huangjin fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach |